Patients Reported Harm From Unapproved Peptide Injections

Regulatory changes have coincided with rising reports of severe health complications among users of these substances.

Updated on Oct. 13, 2026 in Diabetes

Bold flat-color editorial illustration featuring a single glass vial, representing the risks of unregulated medical compounds. — Federal regulators are weighing new oversight for peptides like BPC-157 as thousands of patients report severe health complications from unapproved compounds. AI Illustration. Upload story photo >

Live Poll

Should federal regulators prioritize safety testing over individual access to experimental medical compounds?

More than 1,000 individuals have reported using the peptide BPC-157 to physicians since 2020, even as the market for these unapproved substances continues to grow. These reports follow recent hospitalizations and ongoing debates regarding the oversight of compounds sold through a largely unregulated gray market.

Why it matters

The rise of a $100 million gray market for peptides introduces significant safety risks, as consumers often rely on vendor certificates that fail to screen for sterility. The administration is reportedly drafting new rules for these products while evaluating how to expand access without compromising public safety.

Medical reports indicate that over 1,000 individuals have used BPC-157 since 2020, including cases resulting in hospitalization. These findings emerge as spending on third-party purity testing has fallen 88%, highlighting a growing reliance on unverified products.

The players

FDA Pharmacy Compounding Advisory Committee

An advisory body that provides the Food and Drug Administration with recommendations regarding the compounding of human drugs.

The details

Peptides like BPC-157 are often marketed through private wellness and longevity clinics, though many are sold directly to consumers without FDA approval. Buyers typically depend on vendor-provided certificates of analysis, which often omit essential testing for microbial sterility or chemical impurities. Recently, the FDA Pharmacy Compounding Advisory Committee voted to recommend six of seven studied peptides for inclusion on the 503A bulks list, a move that could alter how these substances are manufactured.

Since 2020, over 1,000 people have reported BPC-157 use to physicians.
During the summer of 2025, two women were hospitalized after injections at a Las Vegas conference.
In July 2026, the FDA Pharmacy Compounding Advisory Committee voted on the 503A bulks list.

Health Landscape

The debate over peptide oversight marks a significant shift in how federal regulators interact with the rapidly expanding longevity and regenerative medicine sector. This development updates the criteria for the 503A bulks list, which governs the safety standards for compounded products.

If you are considering peptide therapy, it is important to discuss the source, purity, and clinical evidence with your physician before starting any treatment. Be particularly cautious of wellness products marketed for longevity that lack robust human clinical trial data or FDA approval.

The takeaway

The use of unapproved peptides like BPC-157 carries significant safety risks, including the potential for severe infection from improperly manufactured substances. If you are offered injectable therapies, confirm the product's origin and discuss the safety profile with a licensed medical professional.